MDMA therapy gets support from prominent research group as FDA weighs action
Green Market Report’s Post
More Relevant Posts
-
A “truly remarkable” form of #LSD has reportedly been granted ‘breakthrough therapy’ status by the US FDA after showing promise against Generalised Anxiety Disorder #GAD in phase 2b clinical trials. > The move comes after a single dose of the lysergide d-tartrate treatment - known as MM120 - achieved a “clinically and statistically significant” reduction in anxiety after a single oral dose. > According to biopharma company MindMed, which is developing the drug and conducted the trials, improvement in GAD symptoms was noted within two days of patients taking the drug. > The data – which also showed a 65% clinical response rate and 48% clinical remission rate after 12 weeks – persuaded the FDA to work closely with MindMed to assess MM120 in larger phase 3 trials. #ScienceForASaferWorld #MentalDisorders #neurodegenerativediseases
FDA Grants Breakthrough Therapy Status To LSD Drug To Treat Anxiety
social-www.forbes.com
To view or add a comment, sign in
-
Patients diagnosed with multiple sclerosis (MS) often face challenges in managing their symptoms effectively, with many struggling to achieve satisfactory control through conventional pharmacological treatments. A retrospective review of medical records involving 141 MS patients undergoing symptom management with medical cannabis (MC) sought to explore its role in comprehensive treatment plans. Over up to four follow-up appointments after MC initiation, significant improvements were noted in various MS symptoms, notably pain relief (72% of patients), spasticity reduction (48% of patients), and enhanced sleep quality (40% of patients). Remarkably, the introduction of MC led to a notable decrease in the use of opioid analgesics, as evidenced by a significant reduction in daily morphine milligram equivalents among patients prescribed opioids (P = .01). While decreases in muscle relaxant and benzodiazepine usage did not reach statistical significance (P > .05), the findings underscored the potential of MC to mitigate the need for conventional medications. Adverse reactions to MC were generally mild, with fatigue reported in only 11% of patients. The study findings suggest that MC holds promise as an adjunctive therapy for MS patients, demonstrating tolerability and efficacy in alleviating symptoms, reducing opioid usage, and enhancing overall well-being. 👉 Read the full study here https://buff.ly/4d4qYjE
To view or add a comment, sign in
-
#WhatsNewInPharmaceuticalIndustry . For your knowing, US FDA just rejected an application from Lykos Therapeutics for #MDMA usage into #PTSD treatment in the past 48 hours. Take a look on the #BBCNEWS page here: https://lnkd.in/gDQhcSDb . Besides, an article from St. Vincent's hospital in #Melbourne disclosed an end of treatment phase of clinical trial for psilocybin (the psychoactive compound in magic mushrooms) treating #anxiety , seems like the import of psychedelic compounds into regular psychiatric treatment could be the next trend. Take a look of the article here: https://lnkd.in/g_3g7p6J since the link isn't working, The Guardians' report here: https://lnkd.in/gPjG_VFn . In my opinion, this is clever since those chemicals' efficacy have been proved for long time, going through different groups of volunteers, which part have been kicking away lots of new drug candidates in early development phase; besides, it's exciting to see further attempts of using these chemicals in a relative positive way, lighting up the potential of future pharmaceutics.
FDA denies MDMA, ecstasy-based drug, to treat PTSD
bbc.com
To view or add a comment, sign in
-
EVALUATION OF THE EFFICACY OF A NEW LOW-LEVEL LASER THERAPY HOME PROTOCOL (B-CURE LASER) IN THE TREATMENT OF TEMPOROMANDIBULAR JOINT DISORDER-RELATED PAIN ‘This preliminary evaluation showed that LLLT and drug therapy have almost the same efficacy in the treatment of pain related to TMJDs’ ‘Statistical analysis showed that treatment was effective’ ‘Several studies have analyzed the application of LLLT in the management of pain associated with TMJDs, but the real innovation that characterizes this trial is the opportunity to perform a new protocol at home.’ Read the full article here: https://lnkd.in/e6AGBP2V Buy a B-CURE Laser to use yourself at home now: https://lnkd.in/ekmvbbDr #lllt #musculoskeletal #pain #chronicpain #actutepain #costeffective #reduceinflammation #research #medicalreview #medicalresearch #bcurelaser #lasertherapy #painreduction #painmanagment #lowlevellasertherapy
Evaluation of the efficacy of a new low-level laser therapy home protocol in the treatment of temporomandibular joint disorder-related pain: A randomized, double-blind, placebo-controlled clinical trial
tandfonline.com
To view or add a comment, sign in
-
Co-Founder & Chief Medical Officer at Accomplish Health | Healthcare Futurist | Clinical Assistant Professor of Medicine - OUHSC
The new cardiometabolic drugs (GLP1s and other hormone-based therapies) are getting more potent in their ability to ameliorate suffering, but with great potential also comes great responsibility. I cannot emphasize this enough: you MUST NOT casually prescribe these meds. This will lead to adverse events. If you are interested in therapy, please work with expert clinics like Accomplish Health and others. [1] Rise in GLP1 overdoses — https://lnkd.in/guHemEfE [2] Adverse GI events linked to GLP1 meds — https://lnkd.in/gJ_fRkBe [3] EMA investigating link between GLP1 meds and suicidal ideation — https://lnkd.in/g5rWpxzW
GLP-1 Agonists and Gastrointestinal Adverse Events
jamanetwork.com
To view or add a comment, sign in
-
Epilepsy Management Enhanced: SK Life Science Announces FDA Approval for Additional XCOPRI® Administration Options The U.S. FDA has approved two additional administration methods for XCOPRI, an antiseizure medication for epilepsy patients. The new methods allow patients to crush the tablets and mix them with water to take orally as a suspension or via a nasogastric tube. This provides enhanced flexibility and accessibility for patients who have trouble swallowing whole tablets. The approval is based on clinical data demonstrating safety, efficacy, and bioequivalence of the alternative administration methods. This provides healthcare professionals and patients with additional options to optimize patient care. SK Life Science is committed to advancing treatment options for neurological disorders and continues to research and develop new treatments for epilepsy and other central nervous system disorders. For more details please click the link! https://lnkd.in/g5DHqtzY #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
Epilepsy Management Enhanced: SK Life Science Announces FDA Approval for Additional XCOPRI® Administration Options
To view or add a comment, sign in
-
🌿 Check out my recent blog post on the role of medical marijuana in managing Multiple Sclerosis (MS)! Recent findings suggest new potential benefits for MS patients. Don’t miss out on the latest insights! https://lnkd.in/eWv59KAD
A PAGE IN MY DIARY — Living with Multiple Sclerosis — Maitri Medicinals
maitrimedicinals.com
To view or add a comment, sign in
-
The FDA has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder. A new drug called MM120 has received the designation of "Breakthrough Therapy" from the FDA. This new drug has similarities to LSD and will be evaluated as a treatment for anxiety. Although we are all busy with Fentanyl, the Nitazines, Cocaine, Tusi, and Methamphetamine, these new drugs coming to market are ones that we should pay attention to. Although the market for these drugs are small, the diversion of these drugs can have consequences in public safety. Understanding MM120: A Comparison to LSD MM120, while emerging as a significant breakthrough in medical therapies, shares certain pharmacological properties with LSD, a substance well-known for its potent psychoactive effects. Both compounds operate within the neural pathways of the brain, influencing neurotransmitter systems that can profoundly affect perception, mood, and cognition. The comparison to LSD is particularly relevant in understanding MM120's potential impact on the brain's serotonergic system, which plays a critical role in regulating various psychological and physiological processes. This similarity draws attention to the importance of comprehensive research and regulatory oversight to ensure that MM120's therapeutic benefits are harnessed responsibly, with a keen eye on minimizing abuse potential and preventing its diversion into illicit channels. Such vigilance is crucial in balancing the innovative therapeutic promise of MM120 with the imperative to safeguard public health and safety.
To view or add a comment, sign in
-
Epilepsy, and its pharmacological treatments, can have serious impacts on a person's life, but therapeutic drug monitoring (TDM) can help. In this study, researchers assessed the reliability and real-life feasibility of patient self-collected volumetric absorptive microsampling (VAMS) for TDM of antiseizure medication (ASMs). The results indicate that self-sampling is a reliable procedure and that VAMS could be an important support tool for TDM, especially for those who live far from their health providers. #MicroSampling #Bioanalysis #Epilepsy https://bit.ly/3vug5qE
Fingerprick volumetric absorptive microsampling for therapeutic drug monitoring of antiseizure medications: Reliability and real-life feasibility in epilepsy patients
sciencedirect.com
To view or add a comment, sign in
-
Targeted Drug Delivery (TDD) therapy isn't just about easing pain; it's a valuable therapy to help patients return to their everyday activities.¹ The Control Workflow™ approach to TDD uses low-dose therapy as a treatment option for chronic pain, offering a practical option to minimize systemic opioid use while maintaining effective pain relief.²,³ Incorporating this approach could assist in overcoming perceived obstacles to TDD therapy. Surgical, device, and drug complications can occur that may be life-threatening or fatal. See risk information here: https://bit.ly/3LrZt7m To learn more about Control Workflow™, check out our webpage for more info: https://lnkd.in/gNJ4Q8_n #MDTPainInterventions #TDD #ControlWorkflow #TDDSynchromedIII ¹ Hamza M, Doleys DM, Saleh IA, et al. A Prospective, Randomized, Single-Blinded, Head-to-Head Long-Term Outcome Study, Comparing Intrathecal (IT) Boluses With Continuous Infusion Trialing Techniques Prior to Implantation of Drug Delivery Systems (DDS) for the Treatment of Severe Intractable Chronic Nonmalignant Pain. Neuromodulation. 2015 Oct;18(7):636-48. ² Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13(10):1304-1313. ³ Grider JS, Etscheidt MA, Harned ME, et al. Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study. Neuromodulation: journal of the International Neuromodulation Society. 2016;19(2):206-219.
To view or add a comment, sign in
4,701 followers